Varian receives FDA exemption for Radiate-VT trial

By staff writers

January 19, 2023 -- Varian, a Siemens Healthineers company, has secured an investigational device exemption by the U.S. Food and Drug Administration (FDA) for the Radiate-VT clinical trial.

The trial will evaluate the safety and efficacy of cardiac radioablation compared with repeat catheter ablation for patients with high-risk refractory ventricular tachycardia. The company said the study will be international, multicenter, and randomized controlled.

Varian also said that initial approval for the trial has been granted for 80 patients at 10 U.S. sites. Total enrollment is planned for 380 patients in up to 30 centers around the world.

Copyright © 2023

To read this and get access to all of the exclusive content on create a free account or sign-in now.

Member Sign In:
MemberID or Email Address:  
Do you have a password?
No, I want a free membership.
Yes, I have a password:  
Forgot your password?
Sign in using your social networking account:
Sign in using your social networking